{"id":"adx-914","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3545036","moleculeType":"Small molecule","molecularWeight":"240.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD47, ADX-914 prevents tumor cells from evading immune detection, allowing the immune system to recognize and attack cancer cells. This mechanism is thought to enhance anti-tumor immune responses.","oneSentence":"ADX-914 is a monoclonal antibody targeting CD47.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:06.436Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06018428","phase":"PHASE2","title":"A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Q32 Bio Inc.","startDate":"2023-09-12","conditions":"Alopecia Areata","enrollment":75},{"nctId":"NCT05509023","phase":"PHASE2","title":"Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Q32 Bio Inc.","startDate":"2022-09-30","conditions":"Atopic Dermatitis","enrollment":102},{"nctId":"NCT04485481","phase":"PHASE1","title":"Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Q32 Bio Inc.","startDate":"2020-09-08","conditions":"Safety Issues","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ADX-914","genericName":"ADX-914","companyName":"Q32 Bio Inc.","companyId":"q32-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ADX-914 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}